Clinical study of switching from intravenous (IV) to subcutaneous (SC) infliximab patients with inflammatory bowel disease
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Infliximab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms REMSWITCH; Remswitch-Lt
Most Recent Events
- 30 Nov 2023 Results reporting long-term efficacy and safety data after a median follow-up of 18 months published in the Alimentary Pharmacology and Therapeutics
- 17 Oct 2023 Results assessing the long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs) treated with or without intensi-fied intravenous regimen, presented at the 31st United European Gastroenterology Week.
- 17 Oct 2023 Results of post hoc analysis , assessing the clinical and pharmacological evolution after switching from IV to SC IFX in IBD patients suffering from obesity to evaluate the feasibility of the switch in this specific population presented at the 31st United European Gastroenterology Week